Attaya Suvannasankha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Attaya Suvannasankha has a total of 223 co-authors. Here are the top co-authors by number of shared publications:
- Brian A. Walker
Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States
25 shared publications - Enze Liu
Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States
23 shared publications - Gareth John Morgan
Multiple Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
23 shared publications - Parvathi Sudha
Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, USA
23 shared publications - Mohammad I. Abu Zaid
Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, USA
22 shared publications - Ola Landgren
Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, USA
22 shared publications
Latest Publications
- Open Access
Genomic characterization of patient derived xenograft models of multiple myeloma reveals selection of multiple pre-existing high risk clones
Multiple myeloma (MM) is a genomically complex malignancy of terminally differentiated plasma cells. Here, we have utilized the SCID-rab patient derived xenograft (PDX) model as a platform to expand scarce primary MM samples across disease stages and major cytogenetic subgroups for comprehensive molecular analysis. The model generated abundant CD138+ cells while retaining key genomic, transcriptomic and proteomic features of corresponding patient tumors. Compared with human myeloma cell lines, PDX cells more closely resembled primary MM in proliferative state and expression of therapeutically relevant targets. Whole genome sequencing (WGS) and single-cell WGS showed that PDXs arose from the selection of pre-existing subclones, including clones harboring high-risk alterations and convergent mechanisms of tumor suppressor inactivation. These findings establish SCID-rab PDX models as a platform for multi-omic profiling, studying clonal evolution, and determining therapeutic response in MM.
Open AccessGenomic characterization of patient derived xenograft models of multiple myeloma reveals selection of multiple pre-existing high risk clones
Multiple myeloma (MM) is a genomically complex malignancy of terminally differentiated plasma cells. Here, we have utilized the SCID-rab patient derived xenograft (PDX) model as a platform to expand scarce primary MM samples across disease stages and major cytogenetic subgroups for comprehensive molecular analysis. The model generated abundant CD138+ cells while retaining key genomic, transcriptomic and proteomic features of corresponding patient tumors. Compared with human myeloma cell lines, PDX cells more closely resembled primary MM in proliferative state and expression of therapeutically relevant targets. Whole genome sequencing (WGS) and single-cell WGS showed that PDXs arose from the selection of pre-existing subclones, including clones harboring high-risk alterations and convergent mechanisms of tumor suppressor inactivation. These findings establish SCID-rab PDX models as a platform for multi-omic profiling, studying clonal evolution, and determining therapeutic response in MM.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Data from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Purpose:This study aims to compare the risk of second primary malignancy (SPM) between patients with multiple myeloma who received chimeric antigen receptor T-cell (CAR T) therapy versus other systemic anticancer therapies (SACT). Experimental Design:Adult patients with multiple myeloma who initiated CAR T therapy or other SACT were identified from Komodo Health claims data and weighted to balance baseline characteristics. Cumulative incidence of SPM was estimated over 24 months, and P values were calculated for the difference between 0 and 24 months. Results:The study included 435 patients who received CAR T therapy and 12,268 patients who received other SACT (median follow-up, 11.8 months). Compared with other SACT, CAR T therapy was associated with similar risks of any SPM (at 24 months, 24.1% vs. 22.3%; P0–24 months = 0.31) and solid SPM (9.1% vs. 11.5%, P0–24 months = 0.32) but significantly higher risk of hematologic SPM (17.9% vs. 13.1%, P0–24 months = 0.04). In a sensitivity analysis requiring ≥ 2 claims to identify an SPM, difference in hematologic SPM risk was attenuated (5.5% vs. 4.9%, P0–24 months = 0.08). Notably, bone marrow examinations were more common after CAR T therapy (e.g., 47% vs. 13% at 0–3 months). Conclusions:In this real-world dataset with relatively short follow-up, patients with multiple myeloma seemed to have a higher risk of hematologic SPM after CAR T therapy compared with other SACT. However, misclassification and detection bias cannot be ruled out. The association warrants further evaluation. Physicians should be vigilant for myeloid malignancies after CAR T therapy.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Purpose:This study aims to compare the risk of second primary malignancy (SPM) between patients with multiple myeloma who received chimeric antigen receptor T-cell (CAR T) therapy versus other systemic anticancer therapies (SACT). Experimental Design:Adult patients with multiple myeloma who initiated CAR T therapy or other SACT were identified from Komodo Health claims data and weighted to balance baseline characteristics. Cumulative incidence of SPM was estimated over 24 months, and P values were calculated for the difference between 0 and 24 months. Results:The study included 435 patients who received CAR T therapy and 12,268 patients who received other SACT (median follow-up, 11.8 months). Compared with other SACT, CAR T therapy was associated with similar risks of any SPM (at 24 months, 24.1% vs. 22.3%; P0–24 months = 0.31) and solid SPM (9.1% vs. 11.5%, P0–24 months = 0.32) but significantly higher risk of hematologic SPM (17.9% vs. 13.1%, P0–24 months = 0.04). In a sensitivity analysis requiring ≥ 2 claims to identify an SPM, difference in hematologic SPM risk was attenuated (5.5% vs. 4.9%, P0–24 months = 0.08). Notably, bone marrow examinations were more common after CAR T therapy (e.g., 47% vs. 13% at 0–3 months). Conclusions:In this real-world dataset with relatively short follow-up, patients with multiple myeloma seemed to have a higher risk of hematologic SPM after CAR T therapy compared with other SACT. However, misclassification and detection bias cannot be ruled out. The association warrants further evaluation. Physicians should be vigilant for myeloid malignancies after CAR T therapy.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Figure S1. Attrition of patients with multiple myeloma and their index treatment periods with CAR T therapy and other SACT LoT
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Figure S1. Attrition of patients with multiple myeloma and their index treatment periods with CAR T therapy and other SACT LoT
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Figure S3. Unweighted proportions of patients with multiple myeloma who received blood smear and bone marrow aspiration/biopsy before and following treatment with individual CAR T therapies
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Figure S3. Unweighted proportions of patients with multiple myeloma who received blood smear and bone marrow aspiration/biopsy before and following treatment with individual CAR T therapies
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Figure S2. Weighted incidence rate (95% CI) of specific types of solid SPM (left) and hematologic SPM (right) in patients with multiple myeloma receiving CAR T therapy or other SACT in the main analysis
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Figure S2. Weighted incidence rate (95% CI) of specific types of solid SPM (left) and hematologic SPM (right) in patients with multiple myeloma receiving CAR T therapy or other SACT in the main analysis
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Table S1. Weighted cumulative incidence of SPM with death as competing risk in patients with multiple myeloma receiving CAR T therapy or other SACT, main analysis and sensitivity analyses
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Table S1. Weighted cumulative incidence of SPM with death as competing risk in patients with multiple myeloma receiving CAR T therapy or other SACT, main analysis and sensitivity analyses
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Table S2. Weighted cumulative incidence of SPM with death as a censoring criterion in patients with multiple myeloma receiving CAR T therapy or other SACT
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Table S2. Weighted cumulative incidence of SPM with death as a censoring criterion in patients with multiple myeloma receiving CAR T therapy or other SACT
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Table S3. Weighted cumulative incidence of SPM with death as competing risk in patients with multiple myeloma receiving CAR T therapy or other SACT and remained at-risk at Month 2, stratified by receipt of post-baseline bone marrow examinations by Month 2
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Table S3. Weighted cumulative incidence of SPM with death as competing risk in patients with multiple myeloma receiving CAR T therapy or other SACT and remained at-risk at Month 2, stratified by receipt of post-baseline bone marrow examinations by Month 2